spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Pharma and Device Packaging and Labelling West Coast 2018

27-28 November 2018
Burlingame, CA

The second edition of the Pharma and Device Packaging and Labeling West Coast was a thought-provoking two days of engaging presentations, discussion and networking.

Chaired by Ms Tennyson Hicks, Associate Program Director at Genentech, the event focused on how to streamline collaboration between packaging and labelling departments, best practices for the best packaging materials and perfect timelines for labelling.

Speakers and delegates representing all of the most important companies in the areas, such as Allergan, Amgen, BioMarin, Genentech participated in an event which saw a fantastic opportunity to have a really insightful view on the challenges faced by different teams within the same company, so that the entry into the market can happen as quickly and successfully as possible.

Following on from this success, Arena International is pleased to announce that this unique event will be returning once again in 2018.

The 2018 program aims to stay abreast of the latest industry trends and operational challenges in the commercial side for biopharma and medical devices companies. If you have an interesting topic proposal, please get in touch with the program director.

 
Print this page
Send to a friend
   
spacer
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

White Papers

News and Press Releases

IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement